JP6232544B2 - サイトメガロウイルスの治療のための組成物及び方法 - Google Patents

サイトメガロウイルスの治療のための組成物及び方法 Download PDF

Info

Publication number
JP6232544B2
JP6232544B2 JP2014540570A JP2014540570A JP6232544B2 JP 6232544 B2 JP6232544 B2 JP 6232544B2 JP 2014540570 A JP2014540570 A JP 2014540570A JP 2014540570 A JP2014540570 A JP 2014540570A JP 6232544 B2 JP6232544 B2 JP 6232544B2
Authority
JP
Japan
Prior art keywords
polypeptide
hcmv
gag
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014540570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505299A (ja
JP2015505299A5 (enExample
Inventor
デーヴィッド， イー． アンデルソン，
デーヴィッド， イー． アンデルソン，
アン−キャサリン フリュキガー，
アン−キャサリン フリュキガー，
シャーロット フリーベルト，
シャーロット フリーベルト，
デーヴィッド クラッツマン，
デーヴィッド クラッツマン，
Original Assignee
ヴァリエーション バイオテクノロジーズ インコーポレイテッド
ヴァリエーション バイオテクノロジーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァリエーション バイオテクノロジーズ インコーポレイテッド, ヴァリエーション バイオテクノロジーズ インコーポレイテッド filed Critical ヴァリエーション バイオテクノロジーズ インコーポレイテッド
Publication of JP2015505299A publication Critical patent/JP2015505299A/ja
Publication of JP2015505299A5 publication Critical patent/JP2015505299A5/ja
Application granted granted Critical
Publication of JP6232544B2 publication Critical patent/JP6232544B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
JP2014540570A 2011-11-11 2012-11-09 サイトメガロウイルスの治療のための組成物及び方法 Active JP6232544B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161558800P 2011-11-11 2011-11-11
US61/558,800 2011-11-11
US201261654157P 2012-06-01 2012-06-01
US61/654,157 2012-06-01
PCT/IB2012/002854 WO2013068847A2 (en) 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017151540A Division JP6657150B2 (ja) 2011-11-11 2017-08-04 サイトメガロウイルスの治療のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2015505299A JP2015505299A (ja) 2015-02-19
JP2015505299A5 JP2015505299A5 (enExample) 2016-01-07
JP6232544B2 true JP6232544B2 (ja) 2017-11-22

Family

ID=48290708

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014540570A Active JP6232544B2 (ja) 2011-11-11 2012-11-09 サイトメガロウイルスの治療のための組成物及び方法
JP2017151540A Active JP6657150B2 (ja) 2011-11-11 2017-08-04 サイトメガロウイルスの治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017151540A Active JP6657150B2 (ja) 2011-11-11 2017-08-04 サイトメガロウイルスの治療のための組成物及び方法

Country Status (14)

Country Link
US (3) US9777043B2 (enExample)
EP (2) EP2776567B1 (enExample)
JP (2) JP6232544B2 (enExample)
KR (2) KR102301463B1 (enExample)
CN (3) CN111995664B (enExample)
AU (3) AU2012335277B2 (enExample)
BR (2) BR112014011229B1 (enExample)
CA (2) CA3166278A1 (enExample)
DK (1) DK2776567T3 (enExample)
ES (1) ES2874233T3 (enExample)
MX (2) MX353189B (enExample)
PT (1) PT2776567T (enExample)
RU (2) RU2737530C1 (enExample)
WO (1) WO2013068847A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12421283B2 (en) 2011-11-11 2025-09-23 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9575055B2 (en) 2009-06-18 2017-02-21 Kiyatec Inc. Co-culture bioreactor system
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013144722A2 (en) * 2012-03-27 2013-10-03 Variation Biotechnologies, Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
SG11201501623PA (en) * 2012-10-30 2015-05-28 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10273285B2 (en) 2014-06-18 2019-04-30 Morphosys Ag Fusion proteins and uses thereof
KR101678740B1 (ko) * 2014-10-24 2016-11-23 단국대학교 천안캠퍼스 산학협력단 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
WO2016149426A1 (en) * 2015-03-16 2016-09-22 The Broad Institute, Inc. Constructs for continuous monitoring of live cells
WO2017068077A1 (en) * 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
CA3002922A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
EP3784276A4 (en) * 2018-04-24 2022-03-16 Merck Sharp & Dohme Corp. SCALABLE CHROMATOGRAPHY PROCEDURE FOR PURIFICATION OF HUMAN CYTOMEGALOVIRUS
JP7575096B2 (ja) 2018-05-04 2024-10-29 スパイバイオテック・リミテッド ワクチン組成物
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
KR20220038608A (ko) * 2019-05-31 2022-03-29 배리에이션 바이오테크놀로지스 아이엔씨. 다형성 교모세포종의 치료를 위한 면역치료 조성물
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle
WO2021048081A1 (en) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
US11857622B2 (en) * 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用
WO2024243675A1 (en) * 2023-06-02 2024-12-05 Variation Biotechnologies Inc. Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) * 1984-10-26 1986-05-22 Green Cross Corp:The ＨＢｓＡｇの精製方法
JP2607712B2 (ja) * 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE19856463B4 (de) * 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
US6413518B1 (en) 1999-09-30 2002-07-02 University Of Washington Immunologically significant herpes simplex virus antigens and methods for identifying and using same
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
PT2311848E (pt) 2002-12-23 2013-10-03 Vical Inc Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line
WO2009120883A2 (en) * 2008-03-26 2009-10-01 Life Technologies Corporation Virus-like particle mediated cellular delivery
GB0907935D0 (en) 2009-05-08 2009-06-24 Henderson Morley Plc Vaccines
AU2012335277B2 (en) 2011-11-11 2018-06-14 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
WO2015089340A1 (en) 2013-12-11 2015-06-18 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12421283B2 (en) 2011-11-11 2025-09-23 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus

Also Published As

Publication number Publication date
JP2015505299A (ja) 2015-02-19
US20140308308A1 (en) 2014-10-16
EP2776567A4 (en) 2015-12-30
RU2737530C1 (ru) 2020-12-03
US12421283B2 (en) 2025-09-23
EP3854416A1 (en) 2021-07-28
WO2013068847A3 (en) 2014-10-30
AU2012335277B2 (en) 2018-06-14
CN111995664A (zh) 2020-11-27
CN111995664B (zh) 2024-08-02
KR20140095556A (ko) 2014-08-01
AU2020264275A1 (en) 2020-11-26
MX387666B (es) 2025-03-18
CN107875382B (zh) 2024-03-08
US20230272013A1 (en) 2023-08-31
BR122019027913B1 (pt) 2021-11-30
CA2889659A1 (en) 2013-05-16
US20170349634A1 (en) 2017-12-07
ES2874233T3 (es) 2021-11-04
AU2012335277A1 (en) 2014-06-12
BR112014011229A2 (pt) 2017-05-09
JP2018023374A (ja) 2018-02-15
EP2776567B1 (en) 2021-01-20
CN104271745A (zh) 2015-01-07
PT2776567T (pt) 2021-05-25
RU2019139064A (ru) 2020-01-27
US11248026B2 (en) 2022-02-15
KR20190104644A (ko) 2019-09-10
CA3166278A1 (en) 2013-05-16
AU2020264275B2 (en) 2023-12-14
KR102340558B1 (ko) 2021-12-21
WO2013068847A2 (en) 2013-05-16
MX353189B (es) 2018-01-05
EP2776567A2 (en) 2014-09-17
AU2018203538A1 (en) 2018-06-07
US9777043B2 (en) 2017-10-03
CN107875382A (zh) 2018-04-06
DK2776567T3 (da) 2021-04-26
JP6657150B2 (ja) 2020-03-04
MX2014005653A (es) 2014-09-04
CA2889659C (en) 2023-03-14
BR112014011229B1 (pt) 2021-10-13
KR102301463B1 (ko) 2021-09-14

Similar Documents

Publication Publication Date Title
US12421283B2 (en) Compositions and methods for treatment of cytomegalovirus
US11717568B2 (en) MVA vaccine for delivery of a UL128 complex and preventing CMV infection
US20240226291A9 (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus
US11253587B2 (en) Vaccine compositions for the treatment of coronavirus
US20220233682A1 (en) Vaccine compositions for the treatment of coronavirus
CN116457011A (zh) 用于治疗冠状病毒的疫苗组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170928

R150 Certificate of patent or registration of utility model

Ref document number: 6232544

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250